Related Experiment Video
Updated: Jul 10, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
[Clinical application of vitamin K for hepatocellular carcinoma]
Toshihiko Mizuta1, Iwata Ozaki
1Saga Medical School, Department of Internal Medicine.
Abstract:
Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

